Innoviva, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Burlingame, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $411 million and a profit of $271 million (its filed statements).
Product businessPharmaceutical PreparationsBurlingame, CAfilings since 20009 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.2 out of ten, 9 of 9 metrics filed: past 6.2 out of ten, present 6.5 out of ten, future 5.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 4.5 out of ten. 3 warning events since 2017; the latest 2023-08-07. 45th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 7.3 out of ten. +13.3% a year over 10 filed years; profitable in 10 of 10. 73rd percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 6.8 out of ten. Share count shrank 1.1% a year. 18% of cash flow returned. Insiders: 0 sales, 0 purchases. 68th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 6.4 out of ten. ROE 23%: 23¢ of profit per shareholder dollar. Leverage 28%: owes 28¢ per asset dollar. 64th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 7.4 out of ten. top 26% of 314 in its family; net margin 65.9%. 74th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.4 out of ten. top 46% of 315 in its family for leadership; chief executive since 2026. 54th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.0 out of ten. top 49% of 272 in its family for room to expand. 51st percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.7 out of ten. top 43% of 307 in its family for growth drivers. 57th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.9 out of ten. top 31% of 234 in its family for expectations against reality. 69th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-25 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-08-24. Filings on record since 2000. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Royalty 57%, Xacduro 18%, Giapreza 18%, Xerava 6%, License and Other Revenue 1%, ZEVTERA under 1%. As tagged in its annual report (Form 10-K, filed 2026-02-25).
Who runs it
Raifeld, Pavel (Chief Executive Officer); Basso, Stephen (Chief Financial Officer); Zhen, Marianne (Chief Accounting Officer); Linden, Josephine (director); Dipaolo, Mark (director); Haimovitz, Jules (director); Schlesinger, Sarah J. (director); Small, Derek A (director). 8 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.